Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings

Type-B monoamine oxidase inhibitors, encompassing selegiline, rasagiline, and safinamide, are available to treat Parkinson’s disease. These drugs ameliorate motor symptoms and improve motor fluctuation in the advanced stages of the disease. There is also evidence supporting the benefit of type-B mon...

Descripción completa

Detalles Bibliográficos
Autores principales: Alborghetti, Marika, Bianchini, Edoardo, De Carolis, Lanfranco, Galli, Silvia, Pontieri, Francesco E., Rinaldi, Domiziana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/
https://www.ncbi.nlm.nih.gov/pubmed/37488838
http://dx.doi.org/10.4103/1673-5374.375299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10479837/
https://www.ncbi.nlm.nih.gov/pubmed/37488838
http://dx.doi.org/10.4103/1673-5374.375299

Ejemplares similares